Quest Diagnostics Q2 2026 Earnings Report

Quest Diagnostics EPS Results

• Actual EPS: N/A
• Consensus EPS: $2.81
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Quest Diagnostics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $2.98 billion
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Quest Diagnostics Announcement Details

• Quarter: Q2 2026
• Date: 7/23/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, July 23, 2026
• Conference Call Time: 8:30AM ET

Quest Diagnostics (NYSE:DGX) (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology. Quest also offers specialized esoteric testing, employer and occupational health testing, clinical trial laboratory services and health information solutions designed to integrate lab data into provider and population health workflows. These capabilities are delivered through laboratory infrastructure, patient collection sites and digital tools that enable ordering, reporting and analytics.

Quest primarily serves the United States healthcare market—providing testing and related services to physician practices, hospitals, payers, employers and governmental agencies—while maintaining capabilities that support international clinical trials and diagnostics initiatives. The company has operated for multiple decades and is structured with centralized laboratory operations, regional service locations and an executive leadership team responsible for strategic, clinical and operational oversight.